Combined chronic myeloid leukaemia and chronic lymphocytic leukaemia in five patients, including one with 17p deletion

• Published in: Internal medicine journal Vol. 51; no. 4; pp. 580 - 584
• Main Authors: Armarego, Michael, Gottlieb, David, Dunlop, Lindsay, Cooney, Julian P.
• Format: Journal Article
• Language: English
• Published: Melbourne John Wiley & Sons Australia, Ltd 01.04.2021; Wiley Subscription Services, Inc
• Subjects: Chronic lymphocytic leukemia; Chronic myeloid leukemia; CLL; CML; combined malignancies; Cytogenetics; Diagnosis; Fludarabine; Hematological diseases; Leukemia; Malignancy; Medical records; Patients; Polymerase chain reaction; Protein-tyrosine kinase; CLL; combined malignancies; CML
• ISSN: 1444-0903; 1445-5994
• DOI: 10.1111/imj.15271

We report a series of five Australian cases of chronic lymphocytic leukaemia (CLL) occurring concurrently with chronic myeloid leukaemia (CML). Patient management including therapies and response together with clinical progress was obtained from medical records and laboratory information systems. Prior to CML diagnosis, all five had a preceding diagnosis of CLL. Three had received prior fludarabine. All received tyrosine kinase inhibitors (TKI). None required subsequent therapy for CLL. One patient had 17p deletion CLL and another patient had normal CLL cytogenetics. All currently have satisfactory blood counts with quantitative polymerase chain reaction for CML showing molecular response. All remain alive. Thus, such cases can be successfully managed by treating each haematological disorder in the usual manner. The control achieved in CML with the TKI enables satisfactory marrow function to recover in patients with concomitant CLL. The role for allograft in patients with dual malignancies is uncertain and needs to be individualised depending on control of each malignancy.